Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.23 USD
Change Today +0.07 / 1.68%
Volume 82.3K
VBLT On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

vascular biogenics ltd (VBLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - $17.02
52 Week Low
03/13/15 - $3.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vascular biogenics ltd (VBLT) Related Bloomberg News

View More Bloomberg News

vascular biogenics ltd (VBLT) Related Businessweek News

No Related Businessweek News Found

vascular biogenics ltd (VBLT) Details

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates include VB-111, a gene-based biologic that has completed Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.

33 Employees
Last Reported Date: 03/25/15
Founded in 2000

vascular biogenics ltd (VBLT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vascular biogenics ltd (VBLT) Key Developments

VBL Therapeutics Reports Interim Topline Results from Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma

VBL Therapeutics announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression (p=0.05). Study results will be presented in conjunction with the American Society of Cancer Oncology (ASCO) Annual Meeting, May 29th-June 2nd, 2015 in Chicago, Illinois. These interim Phase 2 data include 46 patients with rGBM. VB-111 monotherapy was discontinued upon progression in 22 patients who were then treated with bevacizumab alone. The remaining 24 patients, upon disease progression on VB-111 monotherapy, could elect to receive further treatment with VB-111 in combination with bevacizumab. 23 have received combined therapy; one patient is still stable on VB-111 monotherapy at 424 days. VB-111 in combination with bevacizumab demonstrated a statistically significant improvement in overall survival, with median overall survival of 414 days, compared to 235 days in patients on VB-111 followed by bevacizumab alone (p=0.05). VBL's pivotal Phase 3 clinical trial will be led by Dr. Timothy Cloughesy, MD, Professor of Clinical Neurology and dDirector of the Neuro-Oncology Program, UCLA School of Medicine and is expected to initiate in mid-2015 under a special protocol assessment granted by the FDA.

VBL Therapeutics Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

VBL Therapeutics reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss per share was $0.25. Non-GAAP loss per share was $0.14. For the year, the company reported operating loss was $14,778,000 against $15,960,000 a year ago. Comprehensive loss was $17,397,000 against $17,348,000 a year ago. Non-GAAP loss was $12,806,000 against $15,710,000 a year ago. Non-GAAP loss per share attributable to ordinary shareholders, basic and diluted was $0.64 against $1.34 a year ago. Net loss for the full year ended December 31, 2014 was $14.8 million, compared to net loss of $16.0 million for the same period last year.

Vascular Biogenics Ltd. to Report Q4, 2014 Results on Mar 25, 2015

Vascular Biogenics Ltd. announced that they will report Q4, 2014 results on Mar 25, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VBLT:US $4.23 USD +0.07

VBLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VBLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation VBLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VASCULAR BIOGENICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at